Advertisement

Topics

Is the ADHD Market Ready for a Disruptor? An Interview with Highland Therapeutics’ David Lickrish

20:00 EDT 11 Jul 2019 | BioSpace

David Lickrish took time to speak with BioSpace about the companies’ new drug, Jornay PM (methylphenidate HCL Extended-Release CLL Capsules), and how it fits into the overall ADHD therapeutic market.

Original Article: Is the ADHD Market Ready for a Disruptor? An Interview with Highland Therapeutics’ David Lickrish

NEXT ARTICLE

More From BioPortfolio on "Is the ADHD Market Ready for a Disruptor? An Interview with Highland Therapeutics’ David Lickrish"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...